IL6R and COVID-19: Therefore, the sHLH that escorts serious COVID-19 with a well-defined CRS-induced ARDS urgently needs therapeutics interventions based on suppressing CRS, like glucocorticoids and some IL-6R blockers such as tocilizumab (Figure 3A).